These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18592787)

  • 41. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
    Colombo PE; Labaki M; Fabbro M; Bertrand M; Mourregot A; Gutowski M; Saint-Aubert B; Quenet F; Rouanet P; Mollevi C
    Gynecol Oncol; 2014 Nov; 135(2):223-30. PubMed ID: 25220627
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy.
    Eoh KJ; Yoon JW; Lee I; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    J Surg Oncol; 2017 Sep; 116(3):329-336. PubMed ID: 28542980
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
    Solmaz U; Mat E; Levent Dereli M; Turan V; Peker N; Tosun G; Dogan A; Adiyeke M; Ozdemir A; Gungorduk K; Sanci M; Yildirim Y
    J BUON; 2015; 20(2):580-7. PubMed ID: 26011353
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The optimal debulking after neoadjuvant chemotherapy in ovarian cancer: proposal based on interval look during upfront surgery setting treatment.
    Onda T; Yoshikawa H; Yasugi T; Matsumoto K; Taketani Y
    Jpn J Clin Oncol; 2010 Jan; 40(1):36-41. PubMed ID: 19820253
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Management of advanced ovarian cancer in South West Wales - a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort.
    Drews F; Bertelli G; Lutchman-Singh K
    Cancer Epidemiol; 2017 Aug; 49():85-91. PubMed ID: 28599137
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.
    Timmermans M; van der Aa MA; Lalisang RI; Witteveen PO; Van de Vijver KK; Kruitwagen RF; Sonke GS
    Gynecol Oncol; 2018 Sep; 150(3):446-450. PubMed ID: 30001834
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Timing of debulking surgery in advanced ovarian cancer.
    Vergote I; van Gorp T; Amant F; Leunen K; Neven P; Berteloot P
    Int J Gynecol Cancer; 2008; 18 Suppl 1():11-9. PubMed ID: 18336393
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.
    Hou JY; Kelly MG; Yu H; McAlpine JN; Azodi M; Rutherford TJ; Schwartz PE
    Gynecol Oncol; 2007 Apr; 105(1):211-7. PubMed ID: 17239941
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Primary debulking surgery vs. interval debulking surgery for advanced ovarian cancer: review of the literature and meta-analysis.
    Chiofalo B; Bruni S; Certelli C; Sperduti I; Baiocco E; Vizza E
    Minerva Med; 2019 Aug; 110(4):330-340. PubMed ID: 31081304
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The impact of the pathologist on the treatment of epithelial ovarial cancer].
    Zivanovic O; Braun M; Park TW; Kuhn W
    Verh Dtsch Ges Pathol; 2005; 89():101-10. PubMed ID: 18035679
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Debulking surgery for incompletely operated advanced epithelial ovarian carcinoma.
    Gultekin M; Dursun P; Doğan NU; Kolusari A; Yuce K; Ayhan A
    J Surg Oncol; 2009 Sep; 100(3):258-60. PubMed ID: 19347889
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center.
    Lee YJ; Chung YS; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
    J Gynecol Oncol; 2018 Jul; 29(4):e63. PubMed ID: 29770632
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Comparison between Primary Debulking Surgery and Neo-Adjuvant Chemotherapy Followed by Interval Debulking Surgery for Patients with Stage III-IV Ovarian Cancer].
    Shimoji K; Ito K; Tashima L; Tsuruta T; Nakagawa M; Kagawa Y; Takeda Y; Iwata T; Yagi T; Odani C; Ono H; Okubo R; Goto M; Hori K
    Gan To Kagaku Ryoho; 2017 Aug; 44(8):675-679. PubMed ID: 28860439
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer.
    Petrillo M; Zannoni GF; Tortorella L; Pedone Anchora L; Salutari V; Ercoli A; Margariti PA; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2014 Dec; 211(6):632.e1-8. PubMed ID: 24954656
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
    Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer.
    Lim MC; Song YJ; Seo SS; Yoo CW; Kang S; Park SY
    Onkologie; 2010; 33(6):324-30. PubMed ID: 20523098
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neoadjuvant chemotherapy in advanced ovarian cancer: optimal patient selection and response evaluation.
    Cho JH; Kim S; Song YS
    Chin Clin Oncol; 2018 Dec; 7(6):58. PubMed ID: 30509079
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
    Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
    Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.